2024
Association of Sacubitril/Valsartan versus Valsartan with Blood Pressure Changes, and Symptomatic Hypotension: The PARAGLIDE-HF Trial
Fudim M, Cyr D, Ward J, Hernandez A, Lepage S, Morrow D, Sharma K, Claggett B, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Solomon S, Braunwald E, Mentz R, Investigators P. Association of Sacubitril/Valsartan versus Valsartan with Blood Pressure Changes, and Symptomatic Hypotension: The PARAGLIDE-HF Trial. Journal Of Cardiac Failure 2024 PMID: 38802053, DOI: 10.1016/j.cardfail.2024.04.030.Peer-Reviewed Original ResearchLeft ventricular ejection fractionWorsening heart failureBaseline systolic blood pressureSystolic blood pressureVentricular ejection fractionEjection fractionSymptomatic hypotensionNT-proBNPHeart failureBlood pressureLow baseline systolic blood pressureTime-averaged proportional changeMildly reduced ejection fractionPlasma NT-proBNP levelsAssociated with clinical benefitB-type natriuretic peptideNT-proBNP levelsReduced ejection fractionMedian blood pressureBlood pressure changesSH eventsTime-averaged changePrimary endpointNatriuretic peptideRandomized patientsOn‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF
Kittipibul V, Mentz R, Clare R, Wojdyla D, Anstrom K, Eisenstein E, Ambrosy A, Goyal P, Skopicki H, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Greene S. On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF. European Journal Of Heart Failure 2024, 26: 1518-1523. PMID: 38745502, PMCID: PMC11269016, DOI: 10.1002/ejhf.3293.Peer-Reviewed Original ResearchOn-treatment analysisFollow-upAll-cause mortalityHeart failureOn-treatmentNo significant differenceNon-adherencePost-hocSignificant differenceTime of hospital dischargePost hoc analysisDiuretic statusPatients on-treatmentTorsemide groupOpen-labelFurosemide groupRandomized patientsTRANSFORM-HFHF hospitalizationRandomized trialsFurosemidePatientsTorsemideHospital outcomesOutcome differencesImpact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF
Martens P, Greene S, Mentz R, Li S, Wojdyla D, Kapelios C, Mullens W, Hall M, Ketema F, Kim D, Eisenstein E, Anstrom K, Fang J, Pitt B, Velazquez E, Tang W. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF. European Journal Of Heart Failure 2024, 26: 1242-1250. PMID: 38558520, DOI: 10.1002/ejhf.3207.Peer-Reviewed Original ResearchEffect of torsemideBaseline renal functionRenal functionHeart failureKCCQ-CSSRandomized patientsKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreSpectrum of renal functionBaseline kidney dysfunctionCategories of estimated glomerular filtration rateTrial randomized patientsClinical summary scoreAdverse clinical outcomesGlomerular filtration rateAll-cause mortalityTreatment effect modificationModify treatment effectsPost hoc analysisPatient-reported outcomesDiuretic efficacyBaseline eGFRNo significant differenceClinical outcomesKidney dysfunctionFiltration rateTorsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Kapelios C, Greene S, Mentz R, Ikeaba U, Wojdyla D, Anstrom K, Eisenstein E, Pitt B, Velazquez E, Fang J, Investigators T. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circulation Heart Failure 2024, 17: e011246. PMID: 38436075, PMCID: PMC10950535, DOI: 10.1161/circheartfailure.123.011246.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionLVEF groupsKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreMildly reduced left ventricular ejection fractionBaseline left ventricular ejection fractionReduced left ventricular ejection fractionClinical summary scoreHeart failureNo significant differenceEjection fractionClinical outcomesLVEF spectrumSignificant differenceLeft ventricular ejection fraction dataEnd pointsSpectrum of ejection fractionEffect of torsemideRisk of clinical outcomesVentricular ejection fractionStudy end pointBaseline patient characteristicsClinical end pointsSummary scoreAll-cause mortalityPrevalence of comorbiditiesSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysisTorsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure
Krim S, Anand S, Greene S, Chen A, Wojdyla D, Vilaro J, Haught H, Herre J, Eisenstein E, Anstrom K, Pitt B, Velazquez E, Mentz R. Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure. JAMA Cardiology 2024, 9: 182-188. PMID: 37955908, PMCID: PMC10644243, DOI: 10.1001/jamacardio.2023.4776.Peer-Reviewed Original ResearchDe novo heart failureNovo heart failureChronic heart failureHeart failurePatient-reported outcomesCause mortalityHF typeKansas City Cardiomyopathy Questionnaire clinical summary scoreHigher glomerular filtration rateSignificant differencesHeart Failure TrialGlomerular filtration rateClinical summary scoreDiuretic strategyFirst rehospitalizationCause hospitalizationNew onsetTotal hospitalizationsClinical characteristicsClinical profileEjection fractionLoop diureticsFailure TrialHospitalization outcomesNatriuretic peptideEfficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF. Journal Of Cardiac Failure 2024, 30: 312-313. DOI: 10.1016/j.cardfail.2023.10.467.Peer-Reviewed Original ResearchSacubitril/valsartanPIONEER-HFHeart failurePooled analysisNT-proBNPControl therapyDe novo heart failurePlasma NT-proBNP levelsIndependent clinical events committeeIndividual patient-level analysisNovo heart failureNT-proBNP levelsClinical events committeePatient-level analysisCardiovascular deathHemodynamic stabilizationPrimary endpointSymptomatic hypotensionRenal functionMedian ageClinical outcomesRandomized trialsClinical effectsEvents committeeHF events
2023
Current Landscape and Future Directions of Coronary Revascularization in Ischemic Systolic Heart Failure: A Review
Chuy K, Velazquez E, Lansky A, Jamil Y, Ahmad Y. Current Landscape and Future Directions of Coronary Revascularization in Ischemic Systolic Heart Failure: A Review. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101197. PMID: 39131064, PMCID: PMC11307589, DOI: 10.1016/j.jscai.2023.101197.Peer-Reviewed Original ResearchIschemic systolic heart failureSystolic heart failurePercutaneous coronary interventionHeart failureMedical therapyCoronary revascularizationBenefits of PCITrials of PCILeft ventricular systolic dysfunctionPrevalence of HFBenefit of CABGContemporary medical therapyIschemic ventricular dysfunctionCoronary artery bypassVentricular systolic dysfunctionCoronary artery diseaseIschemic heart diseaseAcute cardiac careComparative clinical effectivenessUnmet clinical needRecent revascularizationArtery bypassSystolic dysfunctionVentricular dysfunctionCoronary interventionThe Impact of Ejection Fraction on Major Adverse Limb Events after Lower Extremity Revascularization
Jamil Y, Huttler J, Alameddine D, Wu Z, Zhuo H, Mena-Hurtado C, Velazquez E, Guzman R, Ochoa Chaar C. The Impact of Ejection Fraction on Major Adverse Limb Events after Lower Extremity Revascularization. Annals Of Vascular Surgery 2023, 98: 210-219. PMID: 37802138, DOI: 10.1016/j.avsg.2023.08.009.Peer-Reviewed Original ResearchMajor adverse limb eventsReduced ejection fractionLower extremity revascularizationPeripheral arterial diseaseMALE-free survivalAdverse limb eventsCoronary artery diseaseEjection fractionExtremity revascularizationArtery diseaseLimb eventsChronic limb-threatening ischemiaLimb-threatening ischemiaTricuspid valve regurgitationKaplan-Meier curvesElectronic medical recordsMajor amputationSevere mitralDiastolic dysfunctionEchocardiographic findingsTransthoracic echocardiogramHeart failureValve regurgitationArterial diseaseSingle centerElectronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial
Ghazi L, Yamamoto Y, Fuery M, O'Connor K, Sen S, Samsky M, Riello R, Dhar R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial. European Heart Journal 2023, 44: 4233-4242. PMID: 37650264, DOI: 10.1093/eurheartj/ehad512.Peer-Reviewed Original ResearchGuideline-directed medical therapyAcute heart failureMineralocorticoid receptor antagonistsHeart failureElectronic health recordsGDMT prescriptionPrimary outcomeEnzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitorsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorElectronic health record alertsEvidence-based regimenProviders of patientsReduced ejection fractionCotransporter 2 inhibitorsRelevant patient characteristicsTime of dischargePre-specified criteriaAHF hospitalizationEligible patientsInpatient initiationPatient characteristicsEjection fractionHospitalized patientsMedian ageEffect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Greene S, Velazquez E, Anstrom K, Clare R, DeWald T, Psotka M, Ambrosy A, Stevens G, Rommel J, Alexy T, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Eisenstein E, Mentz R, Investigators O. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation 2023, 148: 124-134. PMID: 37212600, PMCID: PMC10524905, DOI: 10.1161/circulationaha.123.064842.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-2Prespecified secondary end pointsQuality of lifeEffects of torsemideSecondary end pointsHeart failurePatient-reported outcomesKansas City Cardiomyopathy Questionnaire clinical summary scoreNew York Heart Association classPatient Health Questionnaire-2 scoreEnd pointQuestionnaire-2Loop diuretic agentsLoop diuretic useProportion of patientsBaseline health statusClinical summary scoreEjection fraction phenotypeSignificant differencesDiuretic strategyTorsemide groupCause hospitalizationCause mortalityDiuretic usePrimary therapyAngiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure
Mentz R, Ward J, Hernandez A, Lepage S, Morrow D, Sarwat S, Sharma K, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Solomon S, Braunwald E, Investigators P. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1-12. PMID: 37212758, DOI: 10.1016/j.jacc.2023.04.019.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanEjection fractionWHF eventNT-proBNPSymptomatic hypotensionHeart failureAmino-terminal pro-B-type natriuretic peptideTerminal pro-B-type natriuretic peptidePro-B-type natriuretic peptidePlasma NT-proBNP levelsAngiotensin-Neprilysin InhibitionNT-proBNP changesNT-proBNP levelsUrgent HF visitsChronic heart failureHeart failure eventsLarge treatment effectsHF hospitalizationHF visitsCardiovascular deathPrimary endpointRenal functionClinical benefitNatriuretic peptideWeek 4Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
Vaduganathan M, Mentz R, Claggett B, Miao Z, Kulac I, Ward J, Hernandez A, Morrow D, Starling R, Velazquez E, Williamson K, Desai A, Zieroth S, Lefkowitz M, McMurray J, Braunwald E, Solomon S. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal 2023, 44: 2982-2993. PMID: 37210743, PMCID: PMC10424880, DOI: 10.1093/eurheartj/ehad344.Peer-Reviewed Original ResearchConceptsSacubitril/valsartanRenal composite endpointPARAGON-HFHeart failureEjection fractionPooled analysisHF eventsRenal eventsCardiovascular deathComposite endpointLeft ventricular ejection fractionVentricular ejection fractionActive-controlled trialParticipant-level dataPrimary endpointSecondary endpointsClinical outcomesNatriuretic peptideLike patientsTreatment benefitCare settingsPatientsPrimary analysisLVEFValsartanRationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event
Mentz R, Ward J, Hernandez A, Lepage S, Morrow D, Sarwat S, Sharma K, Solomon S, Starling R, Velazquez E, Williamson K, Zieroth S, Braunwald E. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event. Journal Of Cardiac Failure 2023, 29: 922-930. PMID: 36796671, DOI: 10.1016/j.cardfail.2023.02.001.Peer-Reviewed Original ResearchConceptsSac/ValSacubitril/valsartanHeart failure eventsPARAGON-HF trialWHF eventNT-proBNPEjection fractionHeart failureClinical outcomesAmino-terminal pro-B-type natriuretic peptide levelsTerminal pro-B-type natriuretic peptide levelsB-type natriuretic peptide levelsDe novo HFChronic heart failureNatriuretic peptide levelsPrimary efficacy endpointPg/mLEfficacy endpointSafety endpointSecondary endpointsSymptomatic hypotensionBaseline characteristicsRenal functionStable patientsBlack patientsEffect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2022
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisoryAssociation Between Depressive Symptoms and Cardiac Structure and Function in a Peruvian Population
Santiago C, Peña M, Brown T, Shakil S, Januzzi J, Velazquez E, Miranda J, Rivera D, Checkley W. Association Between Depressive Symptoms and Cardiac Structure and Function in a Peruvian Population. Global Heart 2022, 17: 78. PMID: 36382157, PMCID: PMC9615600, DOI: 10.5334/gh.981.Peer-Reviewed Original ResearchConceptsSignificant depressive symptomsDepressive symptomsHeart failureCardiac structureTransthoracic echocardiographyEpidemiological Studies Depression ScaleCRONICAS Cohort StudyDiastolic relaxation velocityCause of disabilityMultivariable linear regressionNon-depressed subjectsCohort studyEchocardiographic measuresMiddle-income countriesWorse outcomesDepressive disorderDepression ScaleCardiac diseaseRelaxation velocityDepression symptomsNon-depressed participantsSymptomsPeruvian populationRelevant covariatesAdult participantsPCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes
Ahmad Y, Petrie M, Jolicoeur E, Madhavan M, Velazquez E, Moses J, Lansky A, Stone G. PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100020. PMID: 39132568, PMCID: PMC11307477, DOI: 10.1016/j.jscai.2022.100020.Peer-Reviewed Original ResearchPercutaneous coronary interventionLeft ventricular systolic dysfunctionCoronary artery diseaseHeart failureComplete revascularizationMedical therapyClinical outcomesClinical trialsCoronary artery bypassVentricular systolic dysfunctionClinical trial evidenceHigh operative riskHigh-risk patientsMajor cardiac surgeryExtent of revascularizationMinority of patientsFuture clinical trialsArtery bypassCause mortalityPeriprocedural complicationsSystolic dysfunctionCoronary interventionOperative riskArtery diseaseCardiac surgery
2020
Impact of Tricuspid Valve Repair for Moderate Tricuspid Regurgitation at the Time of Left Ventricular Assist Device Implantation on the Occurrence of Right Heart Failure
Barac Y, Bishawi M, Milano C, Schroder J, Daneshmand M, Hashmi N, Velazquez E, Rogers J, Patel C, Nicoara A. Impact of Tricuspid Valve Repair for Moderate Tricuspid Regurgitation at the Time of Left Ventricular Assist Device Implantation on the Occurrence of Right Heart Failure. The Journal Of Heart And Lung Transplantation 2020, 39: s444. DOI: 10.1016/j.healun.2020.01.259.Peer-Reviewed Original ResearchRight heart failureModerate tricuspid regurgitationLeft ventricular assist device implantationLate right heart failureVentricular assist device implantationAssist device implantationTricuspid regurgitationTricuspid valve repairLVAD implantationTVR groupTR repairEchocardiographic studyHeart failureStudy cohortDevice implantationValve repairDurable left ventricular assist device implantationEvent-free survival differencesImprovement of TRRight ventricular assist deviceDurable LVAD implantationSevere tricuspid regurgitationSignificant tricuspid regurgitationSingle-center studyKaplan-Meier curvesLIMITED TESTING FOR CORONARY ARTERY DISEASE IN PATIENTS WITH NEW-ONSET HEART FAILURE: FINDINGS FROM GET WITH THE GUIDELINES - HEART FAILURE
O'Connor K, Brophy T, Fonarow G, Blankstein R, Swaminathan R, Xu H, Matsouaka R, Albert N, Velazquez E, Yancy C, Heidenreich P, Hernandez A, DeVore A. LIMITED TESTING FOR CORONARY ARTERY DISEASE IN PATIENTS WITH NEW-ONSET HEART FAILURE: FINDINGS FROM GET WITH THE GUIDELINES - HEART FAILURE. Journal Of The American College Of Cardiology 2020, 75: 866. DOI: 10.1016/s0735-1097(20)31493-5.Peer-Reviewed Original Research